+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endometriosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Endometriosis Type, By Diagnostic Method, By Treatment Method, By Drug Category, By Diagnostics Type, By Distribution Channel, By End-User, Company, Region

  • PDF Icon

    Report

  • 111 Pages
  • November 2022
  • Region: Global
  • TechSci Research
  • ID: 5689420
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The global endometriosis therapeutics market is expected to increase appreciably through 2027. Endometriosis is a disorder characterized by the tissues like the covering of the uterus growing on the outer part of the uterus. It is a type of chronic disease led to serve life-impacting pains during periods, sexual intercourse, urination, chronic pelvic pain, abdominal bloating, nausea, and fatigue. Sometimes extreme levels of these disorders can result in depression, anxiety, and infertility. Across the globe, various initiatives are going to make people, majorly women, aware of the problem; there are many off-label practices due to lack of information. In developing countries, the cost of therapy is creating restrain in growth.

According to WHO, almost 10% of reproductive-age women will be affected by this syndrome or disease globally in 2021. Different government organizations and NGOs are running global campaigns to create Awareness. Launching new advanced products and therapies, Awareness about continuous improvement in patients, and improvement in non-invasive diagnostic methods are one of the major factors responsible for the market. Thus, we can expect a rise in growth and demand in the market share of Endometriosis therapeutics in 2027.

Growing Awareness About the Disease and Treatment in Society

The increasing pervasiveness of gynecological and chronic diseases, an increasing number of people suffering from endometriosis, ongoing R&D activities for advanced endometriosis treatment, and rising demand for hormonal therapies & novel drugs are factors responsible for the growth of the Endometriosis Therapeutics Market. As the population increases, the demand for medical treatment and equipment is increasing in various parts of the world. According to the WHO report, in 2021, almost 190 million reproductive women and girls will be affected by endometriosis worldwide. The above data shows that there is massive potential in the market as the number of potential customers is in the millions and continues its grow as the population increases in developing countries; patients are still not aware of endometriosis and take the wrong drugs and treatment when there are any health problems. Thus, different initiatives and awareness program are going on through social media, Online platforms, newspapers, and other means. Therefore, growing awareness about endometriosis can positively impact the market share.

The large number of women worldwide suffering from endometriosis led to increased demand for treatment. Due to its positive outcome, patients are suggesting the treatment to another patient, and this word of mouth are most impactful in term of awareness. Hence, this factor can positively impact the market share. These increasing demands make the player work for significant technological Advancement in therapeutics and improving treatment. Technological Advancement in segments helps the doctor to treat the patient with minimal surgical cuts on the body, less painful processes, and shorter recovery time. All these efforts make the method more in demand and market share.

Various community, government, and community initiatives are running to uplift women's health. Australia has funded 58 million for improving endometriosis under the national action plan. Janani Shishu Suraksha Yojana, National action plan, Women’s health alliance is an example of global initiatives. These policies led to increasing demand for endometriosis therapeutics in the market. All the factors mentioned above are expected to drive the growth of the Endometriosis Therapeutics Market.

Off-Label Medication Practices are Hurdle in Growth

After so many awareness campaigns are running over the world, many people are still not reachable. Forget about the treatment. They are unaware of endometriosis and take treatment for another problem. Apart from this, in poorer countries, therapy costs are costly that restrain the market growth.

Continuous R&D for Advance Drug Technology is Driving Growth

The evolution of methods and drugs due to technological advancement per market requirements is expected to create impressive growth in the Endometriosis Therapeutics Market. Market players are proposing novel transdermal drug delivery technologies such as topical applicators to overcome the side effects of oral contraceptives and improve efficiency as many women sufferings from endometriosis increase the demand for treatment.

In 2022, Myovant science Limited and Pfizer LLC. Is collaborate and continued to jointly commercialize MYFEMBREE. This medicine is expected to help both companies combine their expertise to deliver the drug quickly and gain market size.

In 2022, Astellas Pharma Inc. announced the outcome of the drug, which is clinical trial version Phase 3, “SKYLIGHT 4“. It is a non-hormonal composite studied for treating sensible to severe vasomotor symptoms associated with menopause (VMS) which will encourage future regulatory organizing submissions.

Market Segmentation

The global endometriosis therapeutics market is segmented based on endometriosis type, diagnostic method, therapeutic method, distribution channel, and end user type. Based on endometriosis type, market is divided into superficial peritoneal lesion, endometrioma, deeply infiltrating endometriosis therapeutics. Based on diagnostic method, market is divided into ultrasound, pelvic examination, laparoscopy, magnetic resonance imaging, and others. Based on treatment method, market is split into hormonal therapy, and pain management. Based on drug category, market is divided into oral contraceptives, progestins, NSAIDs, GnRH analogues, and others. Based on diagnostics type, market is split into pure medical imaging v/s general laboratory use. Based on distribution channel, market is divided into retail pharmacies, hospital pharmacies, online pharmacies. Based on end user, market is divided into hospitals & clinics, ambulatory care center, and others, by company.

Market Players

The Abbott Laboratories, Inc. ; AbbVie, Inc.; Bayer AG; Pfizer, Inc.; Ipsen SA; Evotec SE; Myovant Sciences Ltd.; Philogen S.p.A.; Astellas Pharma Inc.; Orphagen Pharmaceuticals, Inc. are the major market player operating in the Endometriosis Therapeutics Market.

Report Scope:

In this report, global Endometriosis Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Endometriosis Therapeutics Market, by endometriosis type:

  • Superficial Peritoneal Lesion
  • Endometrioma
  • Deeply Infiltrating Endometriosis Therapeutics

Endometriosis Therapeutics Market, by diagnostic method:

  • Ultrasound
  • Pelvic Examination
  • Laparoscopy
  • Magnetic Resonance Imaging
  • Others

Endometriosis Therapeutics Market, by treatment method:

  • Hormonal Therapy
  • Pain Management

Endometriosis Therapeutics, by drug category:

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • Others

Endometriosis Therapeutics, by distribution channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Endometriosis Therapeutics Market, by end user type:

  • Hospitals & Clinics
  • Ambulatory Care Center
  • Others

Medical market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Europe & CIS
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Endometriosis Therapeutics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Endometriosis Therapeutics Market4. Voice of Customer5. Executive Summary6. Clinical Trial Analysis
7. Global Endometriosis Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
7.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
7.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
7.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
7.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
7.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
7.2.6. By Region
7.2.7. By Company (2021)
7.3. Product Market Map
8. North America Endometriosis Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
8.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
8.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
8.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
8.2.6. By Country
8.3. North America: Country Analysis
8.3.1. United States Endometriosis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Endometriosis Type
8.3.1.2.2. By Diagnostic Method
8.3.1.2.3. By Therapeutic Method
8.3.1.2.4. By Distribution Channel
8.3.1.2.5. By End User
8.3.2. Mexico Endometriosis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Endometriosis Type
8.3.2.2.2. By Diagnostic Method
8.3.2.2.3. By Therapeutic Method
8.3.2.2.4. By Distribution Channel
8.3.2.2.5. By End User
8.3.3. Canada Endometriosis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Endometriosis Type
8.3.3.2.2. By Diagnostic Method
8.3.3.2.3. By Therapeutic Method
8.3.3.2.4. By Distribution Channel
8.3.3.2.5. By End User
9. Europe Endometriosis Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
9.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
9.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
9.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
9.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
9.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
9.2.6. By Country
9.3. Europe: Country Analysis
9.3.1. France Endometriosis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Endometriosis Type
9.3.1.2.2. By Diagnostic Method
9.3.1.2.3. By Therapeutic Method
9.3.1.2.4. By Distribution Channel
9.3.1.2.5. By End User
9.3.2. United Kingdom Endometriosis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Endometriosis Type
9.3.2.2.2. By Diagnostic Method
9.3.2.2.3. By Therapeutic Method
9.3.2.2.4. By Distribution Channel
9.3.2.2.5. By End User
9.3.3. Italy Endometriosis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Endometriosis Type
9.3.3.2.2. By Diagnostic Method
9.3.3.2.3. By Therapeutic Method
9.3.3.2.4. By Distribution Channel
9.3.3.2.5. By End User
9.3.4. Germany Endometriosis Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Endometriosis Type
9.3.4.2.2. By Diagnostic Method
9.3.4.2.3. By Therapeutic Method
9.3.4.2.4. By Distribution Channel
9.3.4.2.5. By End User
9.3.5. Spain Endometriosis Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Endometriosis Type
9.3.5.2.2. By Diagnostic Method
9.3.5.2.3. By Therapeutic Method
9.3.5.2.4. By Distribution Channel
9.3.5.2.5. By End User
10. Asia-Pacific Endometriosis Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
10.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
10.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
10.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
10.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
10.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
10.2.6. By Country
10.3. Asia-Pacific: Country Analysis
10.3.1. China Endometriosis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Endometriosis Type
10.3.1.2.2. By Diagnostic Method
10.3.1.2.3. By Therapeutic Method
10.3.1.2.4. By Distribution Channel
10.3.1.2.5. By End User
10.3.2. India Endometriosis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Endometriosis Type
10.3.2.2.2. By Diagnostic Method
10.3.2.2.3. By Therapeutic Method
10.3.2.2.4. By Distribution Channel
10.3.2.2.5. By End User
10.3.3. Japan Endometriosis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Endometriosis Type
10.3.3.2.2. By Diagnostic Method
10.3.3.2.3. By Therapeutic Method
10.3.3.2.4. By Distribution Channel
10.3.3.2.5. By End User
10.3.4. South Korea Endometriosis Therapeutics Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Endometriosis Type
10.3.4.2.2. By Diagnostic Method
10.3.4.2.3. By Therapeutic Method
10.3.4.2.4. By Distribution Channel
10.3.4.2.5. By End User
10.3.5. Australia Endometriosis Therapeutics Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Endometriosis Type
10.3.5.2.2. By Diagnostic Method
10.3.5.2.3. By Therapeutic Method
10.3.5.2.4. By Distribution Channel
10.3.5.2.5. By End User
11. South America Endometriosis Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
11.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
11.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
11.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
11.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
11.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
11.2.6. By Country
11.3. South America: Country Analysis
11.3.1. Brazil Endometriosis Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Endometriosis Type
11.3.1.2.2. By Diagnostic Method
11.3.1.2.3. By Therapeutic Method
11.3.1.2.4. By Distribution Channel
11.3.1.2.5. By End User
11.3.2. Argentina Endometriosis Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Endometriosis Type
11.3.2.2.2. By Diagnostic Method
11.3.2.2.3. By Therapeutic Method
11.3.2.2.4. By Distribution Channel
11.3.2.2.5. By End User
11.3.3. Colombia Endometriosis Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Endometriosis Type
11.3.3.2.2. By Diagnostic Method
11.3.3.2.3. By Therapeutic Method
11.3.3.2.4. By Distribution Channel
11.3.3.2.5. By End User
12. Middle East and Africa Endometriosis Therapeutics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
12.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
12.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
12.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
12.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
12.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
12.2.6. By Country
12.3. MEA: Country Analysis
12.3.1. South Africa Endometriosis Therapeutics Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Endometriosis Type
12.3.1.2.2. By Diagnostic Method
12.3.1.2.3. By Therapeutic Method
12.3.1.2.4. By Distribution Channel
12.3.1.2.5. By End User
12.3.2. UAE Endometriosis Therapeutics Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Endometriosis Type
12.3.2.2.2. By Diagnostic Method
12.3.2.2.3. By Therapeutic Method
12.3.2.2.4. By Distribution Channel
12.3.2.2.5. By End User
12.3.3. Saudi Arabia Endometriosis Therapeutics Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Endometriosis Type
12.3.3.2.2. By Diagnostic Method
12.3.3.2.3. By Therapeutic Method
12.3.3.2.4. By Distribution Channel
12.3.3.2.5. By End User
12.3.4. Egypt Endometriosis Therapeutics Market Outlook
12.3.4.1. Market Size & Forecast
12.3.4.1.1. By Value
12.3.4.2. Market Share & Forecast
12.3.4.2.1. By Endometriosis Type
12.3.4.2.2. By Diagnostic Method
12.3.4.2.3. By Therapeutic Method
12.3.4.2.4. By Distribution Channel
12.3.4.2.5. By End User
12.3.5. Turkey Endometriosis Therapeutics Market Outlook
12.3.5.1. Market Size & Forecast
12.3.5.1.1. By Value
12.3.5.2. Market Share & Forecast
12.3.5.2.1. By Endometriosis Type
12.3.5.2.2. By Diagnostic Method
12.3.5.2.3. By Therapeutic Method
12.3.5.2.4. By Distribution Channel
12.3.5.2.5. By End User
13. Market Dynamics
13.1. Drivers
13.2. Challenges
14. Market Trends & Developments
15. Competitive Landscape
15.1. Abbott Laboratories, Inc.
15.2. AbbVie, Inc.
15.3. Bayer AG
15.4. Pfizer, Inc.
15.5. Ipsen SA
15.6. Evotec SE
15.7. Myovant Sciences Ltd.
15.8. Philogen S.p.A.
15.9. Astellas Pharma Inc.
15.10. Orphagen Pharmaceuticals, Inc.
16. Strategic Recommendations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Bayer AG
  • Pfizer, Inc.
  • Ipsen SA
  • Evotec SE
  • Myovant Sciences Ltd.
  • Philogen S.p.A.
  • Astellas Pharma Inc.
  • Orphagen Pharmaceuticals, Inc.